Cara Therapeutics CFO Thomas Reilly resigns; Richard Makara named interim CFO

Tvardi Therapeutics, Inc.

Thomas Reilly resigns as CFO effective June 15, 2022 to pursue a new opportunity.
Departure is not due to any dispute or disagreement with the company.
Richard Makara, VP Head of Accounting & Controller, assumes interim CFO role.
Makara receives 7,500 RSUs vesting at earlier of Dec 31, 2022 or new CFO appointment.
Makara previously served as interim CFO from Dec 2019 to Oct 2020.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Richard Makara

Interim Chief Financial Officer

TVRD · Tvardi Therapeutics, Inc.

Effective: 2022-06-15
Filed: June 3, 2022, 7:59 PM ET

Effective immediately following Mr. Reilly’s departure, Richard Makara, the Company’s Vice President, Head of Accounting & Controller, will assume Mr. Reilly’s responsibilities on an interim basis.

Departed

Thomas Reilly

Chief Financial Officer

TVRD · Tvardi Therapeutics, Inc.

Effective: 2022-06-15
Successor: Richard Makara
Filed: June 3, 2022, 7:59 PM ET

On May 27, 2022, Thomas Reilly, Chief Financial Officer of Cara Therapeutics, Inc. (the “Company”), gave notice of his resignation, effective on or about June 15, 2022, to pursue a new opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Makara was appointed as Interim Chief Financial Officer at Tvardi Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

Effective immediately following Mr. Reilly’s departure, Richard Makara, the Company’s Vice President, Head of Accounting & Controller, will assume Mr. Reilly’s responsibilities on an interim basis.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Reilly resigned as Chief Financial Officer at Tvardi Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On May 27, 2022, Thomas Reilly, Chief Financial Officer of Cara Therapeutics, Inc. (the “Company”), gave notice of his resignation, effective on or about June 15, 2022, to pursue a new opportunity.

View on SEC.gov

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-068108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.